RxCelerate Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 80

Employees
  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 1

RxCelerate General Information

Description

Operator of an outsourced drug discovery and development platform intended to specialize in non-clinical models of diseases. The company's platform offers bespoke efficacy models, including a study design that combines efficacy and toxicology end-points in a single study wrapper and specializes in bespoke experimental design with data-rich endpoints, enabling researchers to improve the productivity of drug discovery and development.

Contact Information

Formerly Known As
Tcp Biotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Services
Other Pharmaceuticals and Biotechnology
Primary Office
  • B950 Dorothy Hodgkin Building
  • Babraham Research Campus, Babraham
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RxCelerate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jan-2015 Completed Generating Revenue
To view RxCelerate’s complete valuation and funding history, request access »

RxCelerate Patents

RxCelerate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202219662-D0 Reagents for building to a binding site Pending 23-Dec-2022

RxCelerate Executive Team (5)

Name Title Board Seat Contact Info
Jill Reckless Ph.D Co-Founder, Board Member & Chief Executive Officer
Elaine McKilligin Ph.D Board Member & Company Secretary
Nicholas Tait Chief Financial Officer & Board Member
David Grainger Ph.D Co-Founder & Executive Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

RxCelerate Board Members (4)

Name Representing Role Since
David Grainger Ph.D Self Co-Founder & Executive Chairman 000 0000
Elaine McKilligin Ph.D RxCelerate Board Member & Company Secretary 000 0000
Jill Reckless Ph.D RxCelerate Co-Founder, Board Member & Chief Executive Officer 000 0000
Nicholas Tait Self Chief Financial Officer & Board Member 000 0000
To view RxCelerate’s complete board members history, request access »

RxCelerate Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RxCelerate Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Total Medical Ventures Venture Capital Minority 000 0000 000000 0
To view RxCelerate’s complete investors history, request access »

RxCelerate Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 22-Nov-2022 0000000000 Drug Discovery 0000 0000
00000 0000000 22-Sep-2022 00000 0000 00000 Drug Discovery
00000 0000000 20-Jul-2021 00000 0000 0000 Drug Discovery
00000000 05-Feb-2019 0000000000 Other Pharmaceuticals and Biotechnology 00000 000
The Cambridge Partnership 08-May-2018 Merger/Acquisition 00.000 Accounting, Audit and Tax Services (B2B) 0000 0000
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

RxCelerate Subsidiaries (4)

Company Name Industry Location Founded
Methuselah Health Drug Discovery Cambridge, United Kingdom 2014
000 000000000 0000 Accounting, Audit and Tax Services (B2B) Cambridge, United Kingdom 0000
00000000 Other Pharmaceuticals and Biotechnology Cambridge, United Kingdom 0000
00000 0000000000 Biotechnology Cambridge, United Kingdom 0000
To view RxCelerate’s complete subsidiaries history, request access »